Ryan S. Dammerman, MD, PhD
Articles
September 17th 2014
Impact of Atypical Antipsychotic Use Among Adolescents With Attention-Deficit/Hyperactivity Disorder
Vanja Sikirica, PharmD, MPH Steven R. Pliszka, MD Keith A. Betts, PhD Paul Hodgkins, PhD, MSc Thomas M. Samuelson, BA Jipan Xie, MD, PhD M. Haim Erder, PhD Ryan S. Dammerman, MD, PhD Brigitte Robertson, MD Eric Q. Wu, PhD
A retrospective study of the treatment patterns and economic outcomes associated with off-label atypical antipsychotic use in the treatment of adolescents with attention-deficit/hyperactivity disorder.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: November 1st 2024 | Updated: November 21st 2024
Table Multiple Myeloma Trials November 2024
